JNJ vs. MRK: Which Blue-Chip Pharma Stock Should Be in Your Portfolio?

Key Takeaways J&J's pharma and MedTech strength drive growth despite Stelara LOE and ongoing legal challenges.MRK relies heavily on Keytruda, while new drugs like Capvaxive and Winrevair support diversification.J&J's solid cash flows, 63-year dividend record and 2026 growth outlook make it a stronger portfolio choice.Johnson & Johnson (JNJ) and Merck (MRK) are leading U.S. healthcare giants, making them natural peers for a head-to-head comparison.Both companies have a strong presence in oncology, immunology ...